Strides Pharma Science arm gets USFDA nod for Ethacrynic Acid tablets

Topics Strides Pharma | USFDA

Drug firm Strides Pharma Science on Tuesday said its step down subsidiary has received approval from the US health regulator for Ethacrynic Acid tablets, used to treat fluid retention (edema).

The approved product is a generic version of Edecrin tablets, 25 mg, of Bausch Health Americas.

Strides Pharma Global, Singapore, has received approval for Ethacrynic Acid tablets USP in the strengths of 25 mg from the United States Food and Drug Administration (USFDA), Strides Pharma Science said in a regulatory filing.

Quoting IQVIA moving annual total (MAT) August 2020 data, Strides Pharma Science said the US market for Ethacrynic Acid tablets USP, 25 mg, is approximately USD 14 million.

The product will be manufactured at the company's flagship facility at Bengaluru and will be marketed by Strides Pharma in the US market, the company added.

The company has 126 cumulative abbreviated new drug application (ANDA) filings with USFDA of which 92 ANDAs have been approved and 34 are pending for approval.

Ethacrynic acid is in a class of medications called diuretics (water pills). It is used to treat edema (excess fluid held in body tissues) in adults and children caused by medical problems such as cancer, heart, kidney, or liver disease.

Shares of Strides Pharma Science were trading 0.95 per cent higher at Rs 753.60 apiece on BSE.


(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)


Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Business Standard is now on Telegram.
For insightful reports and views on business, markets, politics and other issues, subscribe to our official Telegram channel